Products - Children and young people | Topic

Showing 33 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
18 December 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
7 March 2019
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
21 December 2018
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
26 May 2010
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
28 November 2007
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
27 March 2002
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
23 August 2000
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine for treating Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 33 products

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

Cochlear implants for children and adults with severe to profound deafness (TA566)

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

Dinutuximab beta for treating neuroblastoma (TA538)

Immunosuppressive therapy for kidney transplant in children and young people (TA482)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Fenfluramine for treating Dravet syndrome [ID1109]

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Children and young people Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 33 products

Guidance programme
1 selected